Teahose.
SIGN IN
NEW HERE — WHAT TEAHOSE DOES
We read the entire AI & tech firehose — so you don't have to.
PODPodcastsAll-In, No Priors, Acquired…
NEWNewslettersStratechery, Newcomer…
PAPPapersPhysical AI research
PHProduct Huntdaily launches
VCInvestor ScoutSequoia, a16z, Benchmark…
CLAUDE DISTILLS →
7 reads, 30 sec each — free, 6 AM ET.
+ a live graph of the companies, people & themes underneath.
HOME/PEOPLE/BEN ZERCHER
// PERSON

Ben Zercher

ROLE SENIOR BIOTECH ANALYSTAT PITCHBOOKMENTIONS 1LAST SEEN APRIL 21, 2026
// BIO

Ben Zercher is a senior research analyst covering biotech and pharma at PitchBook, based in the firm's Seattle office. He conducts research on emerging therapeutics, market dynamics, and investment trends across the life sciences sector. Prior to joining PitchBook, he worked in biotech consulting at Qral Group, focusing on commercial strategy and competitive intelligence. He holds a PhD in chemistry from the University of Washington, where his dissertation focused on characterizing proteins with native mass spectrometry and multidimensional ion mobility.

// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
mention·PitchBook News·APRIL 21, 2026

It's hard to call [the Kelonia deal] an overpay right now. This technology should (in theory) have more durable expression than some other approaches, so there's a premium there. — Ben Zercher, Senior Biotech Analyst, PitchBook

AI-extracted from podcast / newsletter / paper summaries. May contain errors.

Ben Zercher — 1 mention on Teahose